Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.02||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||5.98%||Sales Growth - Q/Q||-11.95%||P/E||-86.75|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-4.46%||ROE||-6.74%||ROI||-5.17%|
|Current Ratio||4.98||Quick Ratio||4.25||Long Term Debt/Equity||0.54||Debt Ratio||0.13|
|Gross Margin||82.59%||Operating Margin||-16.48%||Net Profit Margin||-20.35%||Dividend Payout Ratio|
|Cash From Financing Activities||914.79 M||Cash From Investing Activities||-750.87 M||Cash From Operating Activities||-137.81 M||Gross Profit||170.45 M|
|Net Profit||-67.5 M||Operating Profit||-66.02 M||Total Assets||3.66 B||Total Current Assets||1.52 B|
|Total Current Liabilities||305.51 M||Total Debt||655.49 M||Total Liabilities||1.23 B||Total Revenue||203.26 M|
|High 52 week||106.07||Low 52 week||77.67||Last close||91.36||Last change||3.97%|
|RSI||33.47||Average true range||3.1||Beta||1.08||Volume||685.95 K|
|Simple moving average 20 days||-2.92%||Simple moving average 50 days||-0.47%||Simple moving average 200 days||-4.47%|
|Performance Week||-2.8%||Performance Month||-1.42%||Performance Quart||-0.12%||Performance Half||-10.02%|
|Performance Year||1.53%||Performance Year-to-date||7.29%||Volatility daily||1.91%||Volatility weekly||4.28%|
|Volatility monthly||8.76%||Volatility yearly||30.36%||Relative Volume||211.9%||Average Volume||968.77 K|
|New High||New Low|
2019-04-18 10:33:02 | Earnings Preview: BioMarin Pharmaceutical BMRN Q1 Earnings Expected to Decline
2019-04-17 11:18:00 | Forbes Names BioMarin 4th Best Midsize Employer in America
2019-04-17 10:06:46 | As Nasdaq 100 hits record, Apple and Intel could still be buys, says expert
2019-04-16 10:51:02 | New Strong Sell Stocks for April 16th
2019-04-12 07:06:03 | 8 Stocks May Jump on Takeovers as Market Nears Peak
2019-04-09 10:48:29 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
2019-04-03 08:13:00 | Does Sangamo Have the Best Gene Therapy Program Now?
2019-03-31 19:57:35 | Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. NASDAQ:BMRN
2019-03-29 11:15:03 | New Strong Sell Stocks for March 29th
2019-03-28 08:04:41 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
2019-03-27 10:03:02 | New Strong Sell Stocks for March 27th
2019-03-27 09:15:01 | S&P Fights Past Growth Concerns to Reclaim 2800
2019-03-25 10:10:00 | 3 Stocks to Buy Ahead of the Next Market Crash
2019-03-23 09:30:01 | Why Is BioMarin BMRN Down 0.9% Since Last Earnings Report?
2019-03-22 15:01:05 | Analysts Are Mostly Positive on BioMarin Pharmaceutical in March
2019-03-20 16:55:16 | S.F. hotel demand bubbles over, spilling out into the rest of the Bay Area
2019-03-18 10:47:02 | New Strong Sell Stocks for March 18th
2019-03-13 09:15:01 | Boeing Keeps Dow from Joining Rally
2019-03-12 10:26:39 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
2019-03-08 11:09:29 | Did BioMarin Pharmaceutical Inc. NASDAQ:BMRN Insiders Sell Shares?
2019-03-07 07:50:12 | New Strong Sell Stocks for March 7th
2019-03-01 21:29:00 | Why Big Pharma Is Diving Into Gene Therapy
2019-02-28 10:54:03 | Sarepta SRPT Q4 Earnings Lag Estimates, Exondys 51 Sales Up
2019-02-26 15:26:00 | BioMarin Revenue Slips, but Big Picture Looks Dandy
2019-02-26 07:19:00 | 2 More Gene Therapy Stocks on Big Pharma's Buyout Radar
2019-02-25 15:12:37 | Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal
2019-02-25 09:21:00 | MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks
2019-02-24 10:46:09 | Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
2019-02-23 07:54:07 | Edited Transcript of BMRN earnings conference call or presentation 21-Feb-19 9:30pm GMT
2019-02-22 16:21:44 | Can This Biotech Stock Redeem Its Sales Lag With A Strong Gene Therapy?
2019-02-22 10:12:47 | BioMarin Pharmaceutical Inc. BMRN Q4 2018 Earnings Conference Call Transcript
2019-02-22 09:23:02 | BioMarin BMRN Q4 Earnings & Sales Miss, Shares Decline
2019-02-21 17:09:28 | BioMarin: 4Q Earnings Snapshot
2019-02-21 16:05:00 | BioMarin Announces Full Year and Fourth Quarter 2018 Results
2019-02-17 08:14:53 | FOMC minutes, Walmart earnings – What to know in the week ahead
2019-02-14 10:31:03 | BioMarin Pharmaceutical BMRN Reports Next Week: Wall Street Expects Earnings Growth
2019-02-13 08:25:00 | Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education — Emerging Consolidated Expectations, Analyst Ratings
2019-02-09 08:16:00 | Is Sangamo's Gene-Editing Approach a Bust?
2019-02-08 08:02:21 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.